Ugur Sahin - 15 Sep 2026 Form 4 Insider Report for BioNTech SE (BNTX)

Reporting relationship: Chief Executive Officer, 10%+ Owner
Issuer ticker: BNTX
Reported as of: 15 Sep 2026
Net transaction value: -$4,721,976
SEC form: 4
Accepted by SEC: 16 Sep 2026, 16:46:20 UTC
Prior SEC filing: 14 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Humza Bokhari, Attorney-in-Fact

Key filing fact

Ugur Sahin filed Form 4 for BioNTech SE (BNTX) on 16 Sep 2026.

Key facts

This page summarizes Ugur Sahin's Form 4 filing for BioNTech SE (BNTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 16:46.

Change

Previous filing in this sequence was filed on 14 Sep 2026.
Current net transaction value: -$4,721,976.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002123975 Primary reporting owner

Sahin Ugur

Relationship: Chief Executive Officer, 10%+ Owner
Address: C/O BIONTECH SE, AN DER GOLDGRUBE 12, MAINZ, GERMANY
Signature: /s/ Humza Bokhari, Attorney-in-Fact
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BNTX transaction

Ordinary Shares

Sale

Transaction value: $3,280,636
Shares: -34,000
Change %: -5.6%
Price: $96.49
Shares after: 568,209
Date: 15 Sep 2026
Ownership: Direct

BNTX transaction

Ordinary Shares

Sale

Transaction value: $1,441,340
Shares: -15,000
Change %: -2.6%
Price: $96.09
Shares after: 553,209
Date: 16 Sep 2026
Ownership: Direct

BNTX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 39,218,111
Date: 15 Sep 2026
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

SEC remarks

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.